ICOR 2016

Angel Arnaout

Angel Arnaout, Speaker at Cancer Congress
University of Ottawa, Canada
Title : Window of opportunity trials in breast cancer- prioritizing anti-cancer drugs for clinical development


The enormous number of new biological agents aligned with the large investment that is required for their registration is a major challenge for clinical oncology and the pharmaceutical industry. The neoadjuvant scenario is seen as a means of prioritizing drugs for clinical development and is increasingly being exploited for this purpose. The waiting period to surgery for operable breast cancer represents a valuable “window of opportunity” to evaluate novel therapeutic strategies and provide insight into their biological effects in patients who have their cancers intact and are not pretreated. As these trials occur in the waiting period of patients who already have surgery planned as their primary therapy; they are considered incidental, and occur without delay or interference of the patient’s primary, standard of care treatment. Interventional studies performed during this period of a few weeks require significant multidisciplinary collaboration to overcome logistical hurdles. We demonstrate in this session the feasibility and success of conducting several window of opportunity at our cancer center.


Dr. Angel Arnaout is a Breast Surgical Oncologist at the Ottawa Hospital, Associate Professor at the University of Ottawa, Associate Scientist at the Ottawa Hospital Research Institute, and Medical Director of the Breast Health Center in Ottawa, Ontario, Canada. She is the creator innovative programs for breast cancer patients including the Ottawa Hospital Rapid Diagnosis and Support (RADS) Program, The Advanced Multidisciplinary (TEAM) Program of Ottawa, and the “Window of Opportunity” Clinical Trials Platform in Canada. Dr. Arnaout has won numerous national awards for her work including the “Best Innovation in Cancer Care Delivery Award” at the Canadian Ontario Provincial Showcase, the Canadian Association of General Surgeon’s Award, the Canadian Cancer Society Research Award, and the Canadian Breast Cancer Foundation Research Award. Dr. Arnaout has published over 40 scientific papers in peer-reviewed journals.